FLNA trades at Wall Street's consensus target of —.
Last 12 months price action with 12-month analyst target path
The base valuation assumes FLNA achieves its forward estimates and maintains a stable P/E multiple of historical averagesx. This scenario reflects the blended consensus of 12 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Filana Therapeutics, Inc. (FLNA) has a Wall Street consensus price target of N/A, based on estimates from 12 covering analysts. The company has a market capitalization of $22M.
Analyst price targets range from a low of N/A to a high of N/A.
The current analyst consensus rating is Buy, with 8 analysts rating the stock as a Buy or Strong Buy,4 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, FLNA trades at a trailing P/E of -0.5x. Analysts expect EPS to grow +44.4% over the next year.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 ACADACADIA Pharmaceuticals Inc. | $3.6B | $21.23 | $30.05 | +41.5% | Buy | 34.1x | 37 |
 PRAXPraxis Precision Medicines, Inc. | $7.7B | $277.62 | $611.69 | +120.3% | Buy | — | 18 |
 ATNMActinium Pharmaceuticals, Inc. | $45M | $1.43 | — | — | — | — | — |
 AVXLAnavex Life Sciences Corp. | $107M | $1.15 | $11.00 | +856.5% | Buy | — | 13 |
 ACIUAC Immune S.A. | $227M | $2.23 | $8.33 | +273.5% | Buy | — | 9 |
 BIIBBiogen Inc. | $36.7B | $248.35 | $255.00 | +2.7% | Buy | 19.9x | 49 |
 LLYEli Lilly and Company | $1.3T | $1354.00 | $1445.12 | +6.7% | Buy | 38.3x | 46 |
 IONSIonis Pharmaceuticals, Inc. | $6.6B | $39.42 | $84.92 | +115.4% | Buy | — | 33 |
 ALNYAlnylam Pharmaceuticals, Inc. | $20.8B | $155.94 | $330.54 | +112.0% | Buy | 8.5x | 52 |
 IQVIQVIA Holdings Inc. | $44.7B | $271.83 | $289.91 | +6.7% | Buy | 21.0x | 45 |
Quick answers to the most common questions about buying FLNA stock.
The consensus price target for FLNA is $N/A, close to the current price of $0.4527 (N/A% implied move). Based on 12 analyst estimates, the stock appears fairly valued near current levels.
FLNA has a consensus rating of "Buy" based on 12 Wall Street analysts. The rating breakdown is predominantly bullish, with 8 Buy/Strong Buy ratings. The consensus 12-month price target of $N/A implies N/A% upside from current levels.
FLNA's current price is $0.4527 with a consensus target of $N/A (N/A% implied move). Analyst estimates suggest the stock is fairly valued at current levels.
The most bullish Wall Street analyst has a price target of $N/A for FLNA, while the most conservative target is $N/A. The consensus of $N/A represents the median expectation. These targets typically reflect 12-month expectations.
FLNA is moderately covered, with 12 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 8 have Buy ratings, 4 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month FLNA stock forecast based on 12 Wall Street analysts shows a consensus price target of $N/A, with estimates ranging from $N/A (bear case) to $N/A (bull case). The median consensus rating is "Buy".
FLNA appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $N/A target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
FLNA analyst price targets range from $N/A to $N/A, a NaN% tight range reflecting strong analyst consensus. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $N/A consensus represents the middle ground.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.